HPM_442_F_TgCHG_1128

- 1 -

- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus

ヒビスコール液A カタログ

1 2 3 2002 10 Centers for Disease Control and Prevention CDC A 1. 2. 0.2% 3. 1 A 2 3 4 5 6 7 1 1 1. 2. 3. 2 1. 1 0.2% 10 Pseudomonas aeruginosa ATCC 27853 20 20 Proteus vulgaris ATCC 13315 30 20 Escherichia

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,

日本化学療法学会雑誌第61巻第6号

β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

Acecide_ProductsInformation2010PDF.indd

53-0115-00-4PDF 53-0115-00-4PDF INDEX 1 3 9 11 12 16 21 38 39 40 42 43 44 45 46 47 53-0115-00-4PDF 3 1 Critical Semicritical Noncritical Disinfection Sterilization 53-0115-00-4PDF 2 53-0115-00-4PDF O =

日本化学療法学会雑誌第58巻第4号

Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p

相続支払い対策ポイント

150423HC相続資産圧縮対策のポイント

ハピタス のコピー.pages

Copyright (C) All Rights Reserved. 10 12,500 () ( ) ()() 1 : 2 : 3 : 2 4 : 5 : Copyright (C) All Rights Reserved. Copyright (C) All Rights Reserved. Copyright (C) All Rights Reserved. Copyright (C) All

Copyright 2008 All Rights Reserved 2

Copyright 2008 All Rights Reserved 1 Copyright 2008 All Rights Reserved 2 Copyright 2008 All Rights Reserved 3 Copyright 2008 All Rights Reserved 4 Copyright 2008 All Rights Reserved 5 Copyright 2008 All

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium

idwr2015_24

S. boydii S. sonnei K. pneumoniae E. aerogenes E. coli E. cloacae E. aerogenes K. pneumoniae 5 2.40 0.19 0.76 1. 1. 0.34 0.61 0.51 0.62 0.37 0.45 1.49 2SD 1SD 1SD 2SD A SD 0.17 0.77 55 1.22 4. 3.64 7.

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus

公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 3. 感染症発生率感染症発生件数の合計は 981 件であった 人工呼吸器関連肺炎の発生率が 1.5 件 / 1,000 患者 日 (499 件 ) と最も多く 次いでカテーテル関連血流感染症が 0.8 件 /

公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 集中治療室(ICU) 部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 集中治療室 (Intensive Care Unit : ICU) における人工呼吸器関連肺炎 尿路感染症 カテーテル関連血流感染症の発生状況 * を明らかにすることである 集計対象医療機関の各感染症発生率を 1,000 患者

3M_MS Guidebook_2

05 Technique Just Do It 01 Technique 02 Technique 03 Technique 04 Technique 05 Technique Just Do It 06 Technique 07 Technique 08 Technique Group B good idea innovation communication Please Recycle.

R06_01

Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2

日本化学療法学会雑誌第64巻第4号

β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

初心者にもできるアメブロカスタマイズ新2016.pages

Copyright All Rights Reserved. 41 Copyright All Rights Reserved. 60 68 70 6 78 80 Copyright All Rights Reserved. FC2 97 Copyright All Rights Reserved. Copyright All Rights Reserved. Copyright All Rights

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in

- 2 Copyright (C) 2006. All Rights Reserved.

- 2 Copyright (C) 2006. All Rights Reserved. 2-3 Copyright (C) 2006. All Rights Reserved. 70-4 Copyright (C) 2006. All Rights Reserved. ...1...3...7...8 1...9...14...16 2...18...20...21 3...22...23...23...24

untitled

Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium

Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,

1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

Copyright All Rights Reserved. -2 -!

http://ameblo.jp/admarketing/ Copyright All Rights Reserved. -2 -! Copyright All Rights Reserved. -3- Copyright All Rights Reserved. -4- Copyright All Rights Reserved. -5 - Copyright All Rights Reserved.

untitled

http://www.riskdatabank.co.jp The of Japan, Ltd. All rights reserved. 2 The of Japan, Ltd. All rights reserved. 3 The of Japan, Ltd. All rights reserved. 4 The of Japan, Ltd. All rights reserved. 5 The

IPA:セキュアなインターネットサーバー構築に関する調査

Copyright 2003 IPA, All Rights Reserved. Copyright 2003 IPA, All Rights Reserved. Copyright 2003 IPA, All Rights Reserved. Copyright 2003 IPA, All Rights Reserved. Copyright 2003 IPA, All Rights Reserved.

42

41 42 43 44 45 46 47 48 9,527 1,012 331 58 84 90 126 84 106 133 1,012 531 87 82 122 132 108 531 2,037 123 236 935 529 104 110 2,037 498 1,359 417 100 106 78 92 66 133 110 167 423 84 1,359 109 98 150 60

Microsoft Word - 最終版　バックせどりismマニュアル .docx

ism ISM ISM ISM ISM ISM ISM Copyright (c) 2010 All Rights Reserved. Copyright (c) 2010 All Rights Reserved. Copyright (c) 2010 All Rights Reserved. ISM Copyright (c) 2010 All Rights Reserved. Copyright

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

４月号　学会特集号　１２２２４７／１６）一般演題目次

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus

第26回日本環境感染学会総会プログラム・抄録集　Part1

26 26 26 26 26 2009 Klebsiella pneumoniae producing carbapenemasekpcmulti-drug resistant Acinetobacter baumannii MDRAbNew Delhi Metallo--Lactamase-1NDM-1 WHO CDC John BoyceDidier Pittet William RutalaCLA-BSIMark

第65回日本化学療法学会東日本支部総会 抄録

鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma

Fig. 1 The sketch of the neonatal intensive care unit in Tokyo Women's Medical College Hospital. (1979)

Key words: neonatal intensive care unit, bacterial contamination, Pseudomonas, Stophylococcus Fig. 1 The sketch of the neonatal intensive care unit in Tokyo Women's Medical College Hospital. (1979) Table

untitled

mitsuya Copyright (C) 2007. All Rights Reserved. 1/1 mitsuya Copyright (C) 2007. All Rights Reserved. 2/2 mitsuya Copyright (C) 2007. All Rights Reserved. 3/3 mitsuya Copyright (C) 2007. All Rights Reserved.

CHEMO THE RAPY OCT. 1994

bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri

REGZA Tabletガイド

http://toshibaplaces.jp 1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical

健康保険組合のあゆみ_top

(1912) (1951) 2,00024,000 (1954) (1958) (1962) (1965) (1968) (1969) (1971) (1972) (1973) (1974) (1976) (1978) (1980) (1982) (1983) (1984) (1985) (1987) (1988) (1989) (1990) (1991) (1992) (1994) (1995)

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

リバースマップ原稿2

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical

13●53頁●６－７▲院内感染対策▲.ppt

No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia

MacugenInsert01.ai

日本臨床微生物学雑誌第22巻第3号

2012 STEC 231 3 STEC 1) 1) 1) 2) 2) 3) 1) 2) 3) 24 3 6 24 7 19 (Enterohemorrhagic Escherichia coli; EHEC) STEC XM-EHEC 5S A /ViEHEC O157, O26, O111 3 STEC, 14.2 100, XM-EHEC, 7.1 85.7, ViEHEC, 27.6 100

MIC MIC...

50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11

CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),

untitled

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

20 180pixel 180pixel Copyright 2014 Yahoo Japan Corporation. All Rights Reserved.

12 300pixel 300pixel www.yahoo.co.jp Copyright 2014 Yahoo Japan Corporation. All Rights Reserved. 20 180pixel 180pixel Copyright 2014 Yahoo Japan Corporation. All Rights Reserved. 300pixel 300pixel www.yahoo.co.jp

R01

1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200

やよいの顧客管理

1 2 3 4 5 6 7 a a a a a a

弥生給与/やよいの給与計算

弥生 シリーズ

弥生会計 プロフェッショナル/スタンダード/やよいの青色申告

弥生会計/やよいの青色申告

c c c c c 1 c c c c c c c c c c c 2 3 c c 4 a a a a a a a a a

弥生会計 ネットワーク/プロフェッショナル2ユーザー

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

Copyright 2017 JAPAN POST BANK CO., LTD. All Rights Reserved. 1

Copyright 2017 JAPAN POST BANK CO., LTD. All Rights Reserved. 1 Copyright 2017 JAPAN POST BANK CO., LTD. All Rights Reserved. 2 60 50 40 30 20 10 0 20173 20183 Copyright 2017 JAPAN POST BANK CO., LTD.

①

Copyright 2005 Impex.,inc. All Rights Reserved 1 Copyright 2005 Impex.,inc. All Rights Reserved 2 Copyright 2005 Impex.,inc. All Rights Reserved 3 Copyright 2005 Impex.,inc. All Rights Reserved 4 Copyright

CHEMOTHERAPY

VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter

% 11.1% +6.% 4, % %+12.2% 54,16 6.6% EV7, ,183 Copyright 216 JAPAN POST GROUP. All Rights Reserved. 1

216 3 216 5 13 848+4.4% 11.1% +6.% 4,853 495 +2.6% 1 +11.6%+12.2% 54,16 6.6% EV7,829 2 7,183 Copyright 216 JAPAN POST GROUP. All Rights Reserved. 1 15.3 16.3 16.3 11,692 96,57 5.5 % 4,926 4,115 16.5 %

Copyright 2008 NIFTY Corporation All rights reserved. 2

Copyright 2008 NIFTY Corporation All rights reserved. 2 Copyright 2008 NIFTY Corporation All rights reserved. 3 Copyright 2008 NIFTY Corporation All rights reserved. 4 Copyright 2008 NIFTY Corporation

pera1会社概要n

P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P P.11 P.14 P.15 P.16 P.16 P.17 P.19 P.20 P.22 P P P P P P P P P

201628 3 2016 5 13 P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P.10 2016 P.11 P.14 P.15 P.16 P.16 P.17 P.19 P.20 P.22 P.23 10 P.24 11 P.26 12 P.27 13 P.28 14 P.28 15 P.29 16 P.30 17 P.31 P.33 P.34 Copyright 2016 JAPAN

P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P.10 P.12 P.13 P.14 P.14 P.15 P.17 P.18 P.20 P P P P P.25 P.27 P.28 Copyright 2016 JAPAN POST BA

201729 3 1 2016 8 12 P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P.10 P.12 P.13 P.14 P.14 P.15 P.17 P.18 P.20 P.21 10 P.22 11 P.23 12 P.24 13 P.25 P.27 P.28 Copyright 2016 JAPAN POST BANK CO., LTD. All Rights Reserved.

_<74B0><5883><611F><67D3><30DD><30B1><30D7><30ED>_<5FF5><6821>2.pdf

33 The 33rd Annual Meeting of Japanese Society for Infection Prevention and Control The 33rd Annual Meeting of Japanese Society for Infection Prevention and Control The 33rd Annual Meeting of Japanese

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

Copyright 2006 KDDI Corporation. All Rights Reserved page1

Copyright 2006 KDDI Corporation. All Rights Reserved page1 Copyright 2006 KDDI Corporation. All Rights Reserved page2 Copyright 2006 KDDI Corporation. All Rights Reserved page3 Copyright 2006 KDDI Corporation.

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

1000 Copyright(C)2009 All Rights Reserved - 2 -

1000 Copyright(C)2009 All Rights Reserved - 1 - 1000 Copyright(C)2009 All Rights Reserved - 2 - 1000 Copyright(C)2009 All Rights Reserved - 3 - 1000 Copyright(C)2009 All Rights Reserved - 4 - 1000 Copyright(C)2009

いま本文ー校了データ0822.indd

CONTENTS 02 04 06 page 02 1 2 54.0% 38.0% 35.4% 24.2% 71.8% 98.8% 38.1% 23.4% 21.2% 14.5% 56.7% 1 2 10.8% 18.6% 14.5% 18.2% 37.0% 73.281.5 44.729.5 24.336.7 14.733.9 26.622.8 19.824.6 36.6% 30.9% 25.0%

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69

第82 回日本感染症学会総会学術集会後抄録（II）

Corydoras sterbai Kryptopterus bicirrhis Petitella georgiae Xiphophorus maculatus rpob Xba Mycobacterium szulgai Mycobacterium gordonae M. szulgai M. gordonae M. avium M. szulgai M. gordonae M. szulgai

! Copyright 2015 sapoyubi service All Rights Reserved. 2

! Copyright 2015 sapoyubi service All Rights Reserved. 2 ! Copyright 2015 sapoyubi service All Rights Reserved. 3 Copyright 2015 sapoyubi service All Rights Reserved. 4 ! Copyright 2015 sapoyubi service

report03_amanai.pages

-- Monthly Special Interview 03 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 1 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 2 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 3 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED.

report05_sugano.pages

- - Monthly Special Interview 05 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 1 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 2 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 3 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED.

概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia

P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P P.11 P.13 P.15 P.16 P.17 P.17 P.18 P.20 P.21 P.23 P P P P P P P P.31

201729 3 2017 5 15 P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P.10 2017 P.11 P.13 P.15 P.16 P.17 P.17 P.18 P.20 P.21 P.23 P.24 10 P.25 11 P.27 12 P.28 13 P.29 14 P.29 15 P.30 16 P.31 17 P.32 P.34 P.35 Copyright 2017

概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

- 2 Copyright (C) 2009. All Rights Reserved.

- 2 Copyright (C) 2009. All Rights Reserved. - 3 Copyright (C) 2009. All Rights Reserved. - 4 Copyright (C) 2009. All Rights Reserved. - 5 Copyright (C) 2009. All Rights Reserved. - 6 Copyright (C) 2009.

dekiru_asa

11 10 4 4 1 2 3 4 2 4 6 10 12 16 20 2 1 3 1 4 2 5 2 6 3 3 7 8 9 3 3 10 4 1 11 4 2 3 4 5 1 2 3 12 4 5 5 13 14 6 7 8 9 10 11 5 15 6 1 2 3 16 17 1 2 3 6 18 1 2 3 19 6 6 1 2 v 3 20 7 1 2 3 1 7 21 22 2 3 4

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

04-c-„FŒ{›xŒ¾-4.01

544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli

第５号（２００２年）／巻頭

Annual Report of Nagoya University School of Health Sciences K. pneumoniae Pseudomonas aeruginosa Proteus mirabillis MYH9 NMMHC A Thermus aquaticus

Fig. 1 Chemical structure of KW-1070

Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.